Cutamesine

ID: cutamesine

Aliases: SA4503, AGY-94806

Type: compound

Route/form: oral investigational drug

Status: investigational_or_research

Evidence level: early human

Best data tier: early human + disease-context

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_trial, preclinical, review

Linked sources: 3

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• sigma-1 receptor agonist

Optimization domains

• neuroprotection
• cognition
• stroke recovery

Research basis

• Sigma-1 agonism is a plausible neuroplasticity/neuroprotection pathway, with original SA4503 rat cognition/pharmacology data.
• A phase 2 ischemic-stroke recovery trial gives a human clinical anchor.

Limits, risks, and missing evidence

• Clinical efficacy is not established for healthy nootropic use, and stroke-recovery data should not be generalized to healthy cognition.
• Sigma-1 pharmacology is broad and can be overgeneralized from preclinical models.

Risk flags

• investigational
• CNS
• limited human data
• disease context human data

Linked papers, labels, and reviews

1. Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke
   human_trial / ovid_cutamesine_stroke_phase2_2014
   Stroke phase 2 clinical trial; not evidence for general nootropic use.
2. SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties
   preclinical / pubmed_sa4503_cognitive_enhancer_1997
   Original SA4503 sigma-1 binding, acetylcholine, and anti-amnesic rat data.
3. Cognitive Vitality report: Cutamesine
   review / alzdiscovery_cutamesine_2020
   Secondary evidence summary.